FDA-Approved Indications for Gabapentin
Gabapentin has only two FDA-approved indications: (1) management of postherpetic neuralgia in adults, and (2) adjunctive therapy for partial onset seizures (with or without secondary generalization) in adults and pediatric patients 3 years and older with epilepsy 1.
Approved Indications in Detail
1. Postherpetic Neuralgia (PHN)
- Approved for adult patients only
- Dosing starts at 300 mg on Day 1, escalates to 600 mg/day on Day 2, and 900 mg/day on Day 3
- Target maintenance dose: 1800 mg/day (600 mg three times daily)
- Maximum studied dose: 3600 mg/day, though additional benefit above 1800 mg/day has not been demonstrated 1
2. Partial Onset Seizures
Adults and pediatric patients ≥12 years:
- Starting dose: 300 mg three times daily
- Maintenance: 300-600 mg three times daily
- Maximum: 2400 mg/day (well-tolerated in long-term studies); 3600 mg/day has been used short-term 1
Pediatric patients 3-11 years:
- Starting dose: 10-15 mg/kg/day in three divided doses
- Maintenance varies by age:
- Ages 3-4 years: 40 mg/kg/day
- Ages 5-11 years: 25-35 mg/kg/day
- Doses up to 50 mg/kg/day have been well-tolerated 1
Critical Context: Off-Label Use is Widespread
Despite only two FDA-approved indications, gabapentin is extensively prescribed off-label, with off-label use reportedly exceeding FDA-approved uses 2. Recent data shows that among Medicare beneficiaries initiating gabapentin, chronic pain was documented in 32.6% of patients, while epilepsy and postherpetic neuralgia (the approved indications) were documented in fewer than 0.5% of initiators 3. This represents a concerning disconnect between approved indications and actual prescribing patterns.
Common Off-Label Uses (Not FDA-Approved)
Research indicates gabapentin is frequently prescribed for:
- Diabetic neuropathy
- Chronic pain syndromes
- Fibromyalgia
- Migraine prophylaxis
- Bipolar disorder
- Anxiety disorders 4, 2, 5
Important caveat: The evidence supporting most off-label uses is limited, consisting primarily of open-label studies rather than robust randomized controlled trials 2. Clinicians prescribing gabapentin off-label should acknowledge to patients that potential benefits are uncertain for most non-approved uses 4.
Key Prescribing Considerations
Renal Impairment
Dose adjustment is mandatory in patients with compromised renal function:
- CrCl ≥60 mL/min: 900-3600 mg/day
- CrCl 30-59 mL/min: 400-1400 mg/day (BID dosing)
- CrCl 15-29 mL/min: 200-700 mg/day (once daily)
- CrCl <15 mL/min: 100-300 mg/day (once daily)
- Hemodialysis patients require supplemental post-dialysis dosing 1
Safety Concerns
- Co-prescription with opioids is common but concerning: 38.9% of gabapentin initiators had prior opioid use, and 13.2% were co-prescribed gabapentin and opioids at initiation 3
- Withdrawal symptoms can occur after as few as three weeks of treatment 6
- Potential for abuse and diversion exists, leading to reclassification in some jurisdictions 6
- Dose-dependent dizziness and sedation are common adverse effects 7
Discontinuation
Gabapentin should be tapered gradually over a minimum of 1 week when reducing dose, discontinuing, or substituting with alternative medication 1.